Evidence map›Paper›PMID 34000003›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

O-Antigen Targeted Vaccines Against Escherichia coli May Be Useful in Reducing Morbidity, Mortality, and Antimicrobial Resistance.

Guilhem Royer, Olivier Clermont, Bénédicte Condamine, Mélanie Mercier-Darty, Cédric Laouénan, Agnès Lefort, Erick Denamur, Victoire de Lastours, COLIBAFI and SEPTICOLI Groups

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Observational
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Guilhem RoyerUniversité de Paris, Infection Antimicrobials, Modelling and Evolution (IAME), unité mixte de recherche (UMR)1137, Institut National national de la santé et de la recherche médicale (INSERM), Paris, France.
Olivier ClermontUniversité de Paris, Infection Antimicrobials, Modelling and Evolution (IAME), unité mixte de recherche (UMR)1137, Institut National national de la santé et de la recherche médicale (INSERM), Paris, France.
Bénédicte CondamineUniversité de Paris, Infection Antimicrobials, Modelling and Evolution (IAME), unité mixte de recherche (UMR)1137, Institut National national de la santé et de la recherche médicale (INSERM), Paris, France.
Mélanie Mercier-DartyLABGeM, Génomique Métabolique, Genoscope, Institut François Jacob, centre de l'énergie atomique (CEA), Centre nationale de la recherche scientifique (CNRS), Université Paris-Saclay, Evry, France.
Cédric LaouénanUniversité de Paris, Infection Antimicrobials, Modelling and Evolution (IAME), unité mixte de recherche (UMR)1137, Institut National national de la santé et de la recherche médicale (INSERM), Paris, France.
Agnès LefortUniversité de Paris, Infection Antimicrobials, Modelling and Evolution (IAME), unité mixte de recherche (UMR)1137, Institut National national de la santé et de la recherche médicale (INSERM), Paris, France.
Erick DenamurUniversité de Paris, Infection Antimicrobials, Modelling and Evolution (IAME), unité mixte de recherche (UMR)1137, Institut National national de la santé et de la recherche médicale (INSERM), Paris, France.
Victoire de LastoursUniversité de Paris, Infection Antimicrobials, Modelling and Evolution (IAME), unité mixte de recherche (UMR)1137, Institut National national de la santé et de la recherche médicale (INSERM), Paris, France.ORCID 0000-0003-1160-2069
COLIBAFI and SEPTICOLI Groups

Funding

Agence Nationale de la RechercheAssistance Publique-Hôpitaux de Paris AOR 04 053Equipe FRM 2016 DEQ20161136698Ministry of Higher Education and Research, France ANR-15-CE-17-0019-01
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Escherichia coli InfectionsVaccinesAnti-Bacterial AgentsDrug Resistance, BacterialEscherichia coliHumansMorbidityO AntigensAnti-Bacterial AgentsO AntigensVaccines

Identifiers

PMID34000003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.